GRAM POSITIVE BACTERIAL INFECTIONS MARKET ANALYSIS
Gram Positive Bacterial Infections Market Drivers
Increasing drug approvals are expected to propel growth of the gram positive bacterial infections market. For instance, in October 2018, Paratek Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for NUZYRA (for injection), which contains an Omadacycline. This drug is used for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Increasing drug launches are expected to drive the gram positive bacterial infections market growth. For instance, in March 2017, Pfizer launched its new drug, Zavicefta, which contains combination of Avibactam and Ceftazidime. This drug is used for the treatment of intra- abdominal infections.
Gram Positive Bacterial Infections Market Restraints
Antibiotic resistance is the major problem in the treatment of gram positive bacterial infections, which is expected to hamper the market growth. For instance, in October 2018, according to the Centers for Disease Control (CDC) and Prevention, overdose of antibiotics can lead to resistance and around 2 million people are affected with antibiotic resistance in the U.S annually.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
